You are here: Industry Insights > Targeting

News List

Radioconjugates: Targeting for Precision Suzanne Elvidge
May 06, 2025
The development of radioconjugates – targeted molecules designed to carry radionuclides directly to cancerous cells, lowering systemic exposure and increasing the precision of treatment.
Based on the Current Status of Drug Research and Development Targeting the Pathogenesis of Influenza (Part 2) Xiaomichong
July 12, 2024
Influenza is an acute respiratory infectious disease caused by the influenza virus.
Based on the Current Status of Drug Research and Development Targeting the Pathogenesis of Influenza (Part 1) Xiaomichong
July 12, 2024
Influenza is an acute respiratory infectious disease caused by the influenza virus.
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases Biotech Newswire
July 09, 2024
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy.
Live Biotherapeutics: Targeting The Microbiome For The Cancer Treatment Shruti Talashi
March 18, 2024
The quest to create microbial products that can influence cancer outcomes has been rekindled by the mounting evidence of the role that microbiota plays in human health and illness.
Drug Research and Development of Targeting STAT3: Next Outlet for Antitumor Drugs PharmaSources/Yuntian
August 11, 2021
STAT3 is a major member of signal transduction and activating transcription factor (STAT). According to some studies, it is verified that STAT3 can regulate the growth cycle and immune response of cells.
Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT? Technology PRNewswire
January 15, 2025
Axcynsis Therapeutics Pte Ltd ("Axcynsis") announces the clearance of its Investigational New Drug application (IND) by the United States Food and Drug Administration (FDA) of AT03-65 for the treatment of patients with CLDN-6 positive solid tumors.
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology PR Newswire
January 10, 2025
Jan 10, 2025: Menarini Group, its subsidiary Stemline, and Insilico Medicine ink an exclusive license deal. Stemline gets global rights for a pre - clinical oncology small - molecule addressing high unmet needs.
Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS PRNewswire
December 13, 2024
Transcenta Holding Limited announced late-breaking presentation of preclinical study results of novel humanized LIV-1 antibody based ADCs at 2024 San Antonio Breast Cancer Symposium (SABCS).
Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions PR NEWSWIRE
November 20, 2024
Rona Therapeutics presented positive results from the Phase 1 clinical trial of RN0191 at the American Heart Association's (AHA) Annual Scientific Sessions in Chicago, IL, November 16th, 2024.